Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-29
2008-01-29
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07323471
ABSTRACT:
A method for treating or preventing symptoms associated with oral autoimmune diseases comprises treating a patient with an oral topical formulation of azathioprine or a pharmaceutically acceptable salt thereof. The azathioprine formulation may be used in the form of an oral rinse to topically treat areas of oral tissue inflammation and ulceration caused by the onset of oral autoimmune diseases, such as GVHD. The oral topical formulation of azathioprine may also be used in combination with other topical or systemic immunosuppressants or anti-inflammatory drugs.
REFERENCES:
patent: 3056785 (1962-02-01), Hitchings et al.
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5204329 (1993-04-01), Ackerman et al.
patent: 5310545 (1994-05-01), Eisen
patent: 5540931 (1996-07-01), Hewitt et al.
patent: 5578609 (1996-11-01), Batt et al.
patent: 5637616 (1997-06-01), Sharpe et al.
patent: 5639759 (1997-06-01), Magolda et al.
patent: 5691343 (1997-11-01), Sandborn
patent: 5716648 (1998-02-01), Halskov et al.
patent: 5733915 (1998-03-01), Sandborn et al.
patent: 5905081 (1999-05-01), Sandborn
patent: WO-97/31921 (1997-09-01), None
Eggleston, et al., Treatment of Aphthous Ulceration with Topical Azathioprine, British Journal of Oral Surgery (1972), 9: 233-236.
Halliday, GM, Knight, BA, Muller, HK. Reduction In Murine Langerhans Cell ATPase Staining Following Topical But Not Systemic Treatment with Steroid and Non-Steroid Immunosuppressants. Br J Dermatol 1986; 114:83-89.
Mornington, B. The Place of Azathioprine in the Treatment of Auto-Immune Diseases. Leb Med J 1973; 26(1): 21-30.
Woo, SB, Lee, SJ, Schubert, MM. Graft-vs.-host disease. Crit Rev Oral Biol Med 1997; 8(2):201-216.
Schubert, MM, Sullivan, KM. Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 1990; (9):135-143.
Nakamura, S, Hiroki, A, Shinohara, M, et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82(5):556-563.
Epstein JB, Reece, DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994; 13:81-86.
Epstein JB, Truelove, EL. Topical cyclosporin in a bioadhesive for treatment of oral lichenond mucosal reaction Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82:532-536.
Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptourine, cyclosporin, and methotrexate. Am J Gastroenterol 1996; 91(3):423-433.
Winklestein A. The effects of azathioprine and 6-MP on immunity. J Immunopharmacol 1979; 1:429-454.
Brogan M, Hiserodt J, Oliver M, et al. The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol 1985; 5:204-11.
Brogan M, Stevens R, Hiserodt J, et al. Effects of 6-MP on the impaired in vivo humoral responsiveness in Crohn's disease. Gastroenterol 1984; 86:A1035.
Lozada F. Prednisone and azathioprine in the treatment of patients with vesiculoerosive oral diseases. Oral Surg Oral Med Oral Pathol 1981; 52(3):257-260.
Robinson JR, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris. A review of the literature and a report on the management of the 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:349-355.
Lear, JT, English, JSC. Erosive and generalized lichen planus responsive to azathioprine. Clin Exper Derm 1996; 21:56-57.
Allen LV Jr, Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm 1996; 53:1944-1949.
Eggleston DJ, Nally FF. Treatment of aphthous ulceration with topical azathioprine. A double blind trial. Br J Oral Surg 1972; 9(3):233-236.
Suchko VI, Mashchenko IS. Local use of an azathioprine suspension in a dimexide solution in the combined treatment of parodontosis. Stomologica (Mosk) 1981; 60(3): 28-30.
Elliot JH, Leibowitz HM. Chemotherapeutic immunosuppression of the corneal graft reaction. 3 Topical azathioprine. Arch Opthalmol 1966; 76(5):709-711.
Mackay IR, Bignell JL, Smith PH, Crawford BA. Prevention of corneal-graft failure with the immunosuppressive drug azathioprine. Lancet 1967; 514 (2):479-482.
Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci 1994; 39(9):1885-1892.
Stotland BR, Lichtenstein GR. Newer treatments for inflammatory bowel disease. Prim Care 1996; 3(3):577-608.
Zins BJ, Sandborn WJ, McKinney JA, et al. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol 1997; 37:38-46.
Vans Os EC, Zins WJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996; 39:63-68.
Epstein JB, Priddy RW, Sherlock CH. Hairy leukoplakia-like lesions in immunosuppressed patients following bone marrow transplantation. Transplantation 1988; 46:462-4.
Epstein JB, Sherlock CH, Wolber RA. Hairy leukoplakia after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1993; 75:690-5.
Scully, C, Paes de Llmeida, O, Porter, SR, Gilkes, JJH. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 1999; 140:84-89.
Lever, WF. Pemphigus and pemphigoid. A review of the advances made since 1964. J Amer Acad Dermatol. 1979; 1(1):2-31.
Anstey, A, Lear, JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs 1998; 9(1):33-47.
Glied, M, Rico, JM. Treatment of autoimmune blistering diseases. Dermatol Clin 1999; 17(2):431-330.
Eisen, D, Ellis, CN, et al. Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. New Engl J Med 1990; 323(5):290-294.
Ho, VC and Conklin, RJ. Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. New Engl J Med 1991; 325(6):435.
Eisen, D, Griffiths, CEM et al. Cyclosporin Wash for Oral Lichen Planus. Lancet 1990; 335:535-536.
Eisen, D, Ellis, CN, Voorhees, JJ. Topical cyclosporine for oral bullous disorders. J Amer Acad Dermatol 1990; 23(5):936-937.
Eisen, D, Ellis, CN. Topical Cyclosporine for Oral Mucosal Disorders. J Amer Acad Dermatol 1990; 23(6):1259-1264.
Volc-Platzer, B, Hönigsmann, H et al. Photochemotherapy Improves Chronic Cutaneous Graft-Versus-Host Disease.
Farthing, PM, Maragou, P et al. Characteristics Of The Oral Lesions In Patients With Cutaneous Recurrent Erythema Multiforme. J Oral Path Med 1995; 24:9-13.
Plauth, M, Jenss, H, Meyle, J. Oral Manifestations of Crohn's Disease: An Analysis of 79 Cases. J Clin Gastroenterol 1991; 13(1):29-71.
Chemical Abstracts Services, No. 66CA:64312, Rhomburg et al., “Immunosuppressive Therapy in Internal Medicine”, Schweiz. Med. Wochenschr. vol. 97(8), pp. 255-259, 1967.
Chemical Abstracts Services, No. 72CA:39197, Salmon et al., “Treatment of autoimmune diseases with antimitotic agents”, Arch. Belg. Dermatol. Syphiligr., vol. 24(3) pp. 297-309, 1968.
Catalyst Law Group
DOR Biopharma, Inc.
Hui San-ming
Kohn David M.
LandOfFree
Topical azathioprine for the treatment of oral autoimmune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical azathioprine for the treatment of oral autoimmune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical azathioprine for the treatment of oral autoimmune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813434